Sanofi in talks to sell 50% stake in consumer health business to CD&R
Adds French finance ministry comments in paragraphs 7-9
PARIS, Oct 11 (Reuters) -Sanofi SASY.PA has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on Friday.
The announcement confirms an earlier Reuters report that it was closing in on a sale estimated at around 15 billion euros ($16.41 billion).
Sanofi did not disclose any financial details of the potential deal, and said further updates would be provided in due course. Shares in the group were down 0.46% at 0717 GMT.
The company said in October 2023 that it was reviewing potential scenarios to separate out its consumer healthcare business, as it seeks to shore up new drug development spending at its core business
In September, Bloomberg reported that Sanofi had received a bid from CD&R as well as from French rival PAI Partners for the Opella business.
Opella employs more than 11,000 people and owns brands like the painkiller Doliprane, popular in its home market.
The French finance ministry said in a statement that CD&R was a "serious investment fund" with positive prospects for Opella's development and its plants in France.
It added that it would require economic commitments from Sanofi and CD&R including guaranteeing that the business's headquarters and decision-making centres would remain in France, and protection of its industrial footprint in the country.
"This proposed sale does not call into question the production in France of Doliprane or other essential medicines produced by Opella on our territory, nor the supply of these medicines to the market. This is naturally part of the commitments requested," it added.
Rival Johnson & Johnson JNJ.N hived off its consumer health business Kenvue KVUE.N in May last year, while GSK GSK.L and Pfizer PFE.N spun off their consumer divisions in 2022.
($1 = 0.9143 euros)
Reporting by Piotr Lipinski and Dominique Patton; Editing by Jan Harvey and Jane Merriman
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
